Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)

Market Cap	16.01B
Revenue (ttm)	11.50B
Net Income (ttm)	1.08B
Shares Out	1.34B
EPS (ttm)	0.81
PE Ratio	14.79
Forward PE	11.94
Dividend	0.20 (1.68%)
Ex-Dividend Date	Sep 20, 2024

Volume	12,630,551
Open	12.27
Previous Close	12.28
Day's Range	11.94 - 12.33
52-Week Range	7.61 - 14.41
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Shanghai Shyndec Pharmaceutical

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, 7-ADCA, 7-ACA, D-7ACA, penicillin industrial potassium; pharmaceutical intermediates, anti-infective pharmaceutical intermediates salt, ceftriaxone sodium crude salt; and amoxicillin, clavulanic acid series, azithromycin, and ceftriaxone sodium. It also provides anti-infective pharmaceutical raw materials; urogenital system pharmaceutical raw materials, systemic anti-infective dru...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 11,608
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600420

Financial Performance

In 2023, Shanghai Shyndec Pharmaceutical's revenue was 12.07 billion, a decrease of -6.86% compared to the previous year's 12.96 billion. Earnings were 691.88 million, an increase of 10.21%.